Moroxite AB reports positive outcome for Xerafuse™ as a bone graft extender (BGE)

March 30, 2026

Moroxite AB, a Swedish company specialized in innovative implants for spinal fusion, reports positive outcome for Xerafuse™ as a bone graft extender (BGE).

The lead researchers were MD Gintare Lukoševičiūtė and Associate professor Deepak Raina at Lund University, Sweden in collaboration with spine centres in Denmark, Germany, and Lithuania.

The team evaluated a novel preset calcium sulphate dihydrate /hydroxyapatite, Xerafuse™, as a BGE using an acknowledged rabbit posterolateral lumbar spinal fusion model.

Study aims and findings:

1. To investigate spinal fusion outcome for Xerafuse™ as a BGE compared to autologous bone graft (ABG) at 4 and 12 weeks with assessment using mechanical testing, X-ray, Micro CT and histology.

Result: At 12 weeks, Xerafuse™ BGE demonstrated fusion rates across all assessment modalities and was non-inferior to ABG alone. 

2. To investigate whether quantitative micro-CT 3 D morphometry discriminated between a ceramic material and new bone.

Result: Micro-CT Morphometry could dichotomise between a BGE and new bone.

3. To investigate whether it was possible to longitudinally assess total bone and residual material volumes in spinal fusion. 

Result: Total bone volume increased longitudinally in BGE group and was significantly higher compared to autograft group at 12 weeks.

Dr. Stefan Zwingenberger, Professor at University hospital in Greifswald, Germany said-

´The shortage and impaired quality of donor bone especially in an ageing population affected by osteoporosis has led to that BGE often are combined with autograft in spinal fusion. New BGE needs to show safety data and be non-inferior to autograft verified in validated preclinical studies. Xerafuse™, a novel biphasic ceramic has met these requirements´. 

For additional information contact CEO fredrik.lindberg@moroxiteab.com and to know more about us, please visit www.moroxiteab.com